PL3010513T3 - Skojarzenie RO5503781 i kapecytabiny do leczenia raka - Google Patents
Skojarzenie RO5503781 i kapecytabiny do leczenia rakaInfo
- Publication number
- PL3010513T3 PL3010513T3 PL14732136T PL14732136T PL3010513T3 PL 3010513 T3 PL3010513 T3 PL 3010513T3 PL 14732136 T PL14732136 T PL 14732136T PL 14732136 T PL14732136 T PL 14732136T PL 3010513 T3 PL3010513 T3 PL 3010513T3
- Authority
- PL
- Poland
- Prior art keywords
- capecitabine
- combination
- cancer therapy
- cancer
- therapy
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title 1
- 229960004117 capecitabine Drugs 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836894P | 2013-06-19 | 2013-06-19 | |
| PCT/EP2014/062490 WO2014202492A1 (en) | 2013-06-19 | 2014-06-16 | Combination of ro5503781 and capecitabine for cancer therapy |
| EP14732136.8A EP3010513B1 (en) | 2013-06-19 | 2014-06-16 | Combination of ro5503781 and capecitabine for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3010513T3 true PL3010513T3 (pl) | 2019-11-29 |
Family
ID=50981495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14732136T PL3010513T3 (pl) | 2013-06-19 | 2014-06-16 | Skojarzenie RO5503781 i kapecytabiny do leczenia raka |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160129033A1 (pl) |
| EP (1) | EP3010513B1 (pl) |
| JP (1) | JP6239745B2 (pl) |
| KR (1) | KR20160007662A (pl) |
| CN (1) | CN105307660A (pl) |
| BR (1) | BR112015029658A2 (pl) |
| CA (1) | CA2912816A1 (pl) |
| ES (1) | ES2741003T3 (pl) |
| HK (1) | HK1214502A1 (pl) |
| MX (1) | MX2015016893A (pl) |
| PL (1) | PL3010513T3 (pl) |
| RU (1) | RU2015152577A (pl) |
| TR (1) | TR201910701T4 (pl) |
| WO (1) | WO2014202492A1 (pl) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050227932A1 (en) * | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| WO2007107543A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| ES2431564T3 (es) * | 2006-03-22 | 2013-11-27 | Janssen Pharmaceutica N.V. | Inhibidores de la interacción entre MDM2 y p53 |
| WO2008034039A2 (en) * | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
| JP5053674B2 (ja) * | 2007-03-26 | 2012-10-17 | テルモ株式会社 | 耳式体温計 |
| CN115990181A (zh) * | 2008-08-04 | 2023-04-21 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-16 MX MX2015016893A patent/MX2015016893A/es unknown
- 2014-06-16 PL PL14732136T patent/PL3010513T3/pl unknown
- 2014-06-16 CA CA2912816A patent/CA2912816A1/en not_active Abandoned
- 2014-06-16 RU RU2015152577A patent/RU2015152577A/ru not_active Application Discontinuation
- 2014-06-16 ES ES14732136T patent/ES2741003T3/es active Active
- 2014-06-16 HK HK16102348.7A patent/HK1214502A1/zh unknown
- 2014-06-16 US US14/896,716 patent/US20160129033A1/en not_active Abandoned
- 2014-06-16 TR TR2019/10701T patent/TR201910701T4/tr unknown
- 2014-06-16 BR BR112015029658A patent/BR112015029658A2/pt not_active IP Right Cessation
- 2014-06-16 EP EP14732136.8A patent/EP3010513B1/en not_active Not-in-force
- 2014-06-16 KR KR1020157035720A patent/KR20160007662A/ko not_active Ceased
- 2014-06-16 CN CN201480033396.8A patent/CN105307660A/zh active Pending
- 2014-06-16 WO PCT/EP2014/062490 patent/WO2014202492A1/en not_active Ceased
- 2014-06-16 JP JP2016520395A patent/JP6239745B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016522228A (ja) | 2016-07-28 |
| WO2014202492A1 (en) | 2014-12-24 |
| CN105307660A (zh) | 2016-02-03 |
| CA2912816A1 (en) | 2014-12-24 |
| EP3010513A1 (en) | 2016-04-27 |
| MX2015016893A (es) | 2016-04-07 |
| HK1214502A1 (zh) | 2016-07-29 |
| US20160129033A1 (en) | 2016-05-12 |
| KR20160007662A (ko) | 2016-01-20 |
| BR112015029658A2 (pt) | 2017-07-25 |
| EP3010513B1 (en) | 2019-06-05 |
| JP6239745B2 (ja) | 2017-11-29 |
| TR201910701T4 (tr) | 2019-08-21 |
| ES2741003T3 (es) | 2020-02-07 |
| RU2015152577A (ru) | 2017-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| PL3033086T3 (pl) | Terapia skojarzona do leczenia nowotworów złośliwych | |
| IL245731A0 (en) | Combined treatment for cancer | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| GB201322725D0 (en) | Cancer therapy | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| SG10201913730RA (en) | Cancer therapy | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| SG11201508878WA (en) | Methods of treating cancer | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| SG11201507847UA (en) | Cancer therapy | |
| ZA201507762B (en) | Methods of treating cancer | |
| GB201403083D0 (en) | Treatment of cancer | |
| EP2961412A4 (en) | CANCER THERAPY | |
| PL3010508T3 (pl) | Skojarzenie RO5503781, kapecytabiny i oksaliplatyny do leczenia raka | |
| PL3010513T3 (pl) | Skojarzenie RO5503781 i kapecytabiny do leczenia raka | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer |